AstraZeneca PLC (AZN) Stock : Jumps 7% as Revenue Rises 7% and Core EPS Gains 14%

TLDR AstraZeneca stock climbs 7% as revenue reaches $46.9 billion in nine months. AstraZeneca core EPS rises 14% to $8 as nine-month operating profit increases. Oncology revenue grows 16% to $21.9 billion, leading AstraZeneca’s therapy areas. AstraZeneca secures 47 regional approvals, including four newly approved medicines. AstraZeneca maintains 2026 guidance as its 2027 pipeline targets [...]

The post AstraZeneca PLC (AZN) Stock : Jumps 7% as Revenue Rises 7% and Core EPS Gains 14% appeared first on Blockonomi.